Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence.

about

Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence.

Item

http://www.wikidata.org/entity/Q47741252

description

2017 nî lūn-bûn

@nan

2017 թվականի հոկտեմբերին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

name

Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence.

@en

Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence.

@nl

type

Item

label

Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence.

@en

Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence.

@nl

prefLabel

Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence.

@en

Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence.

@nl

P1476

Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence

@en

P2093

Amanda N Basto

http://www.w3.org/2001/XMLSchema#string

Meredith L Howard

http://www.w3.org/2001/XMLSchema#string

P2860

Dabigatran versus warfarin in patients with atrial fibrillation

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

Apixaban versus warfarin in patients with atrial fibrillation

Edoxaban versus warfarin in patients with atrial fibrillation

Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association

A comparison of rate control and rhythm control in patients with atrial fibrillation.

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial

Non-vitamin K antagonist oral anticoagulants in the cardioversion of patients with atrial fibrillation: systematic review and meta-analysis.

Outcomes After Cardioversion in Atrial Fibrillation Patients Treated with Non-Vitamin K Antagonist Oral Anticoagulants (NOACs): Insights from a Meta-Analysis.

P304

277-284

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1060028017737095

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Caitlin M Gibson

P577

2017-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29025267

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation